Drug intelligence / Profile preview

CF2201

Development stage: Preclinical
Lead developer: Zhongke CELFULL
Administration: Oral

Overview

CF2201 is a nutraceutical candidate being developed by Zhongke CELFULL Mitochondrial Medicine for the management of depression (antidepression). As part of the company's focus on mitochondrial medicine, the product is likely designed to address depressive symptoms by supporting or optimizing mitochondrial function, although its specific active ingredients and molecular targets have not been disclosed. It is currently in the Technology Development (TechDev) phase of the company's nutraceutical pipeline, which precedes product development and launch.

Beyond the preview

Go deeper on CF2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF2201.

Explore the full profile